The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (PEC-MASLD)
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomised, Placebo-Controlled, Dietary Intervention Study
Sponsor: Nottingham University Hospitals NHS Trust
Listed as NCT07093346, this NA trial focuses on MASLD and MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and remains actively recruiting participants. Sponsored by Nottingham University Hospitals NHS Trust, it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recordedEligibility Summary
No eligibility information available.
Contact Information
- Nottingham University Hospitals NHS Trust
- University of Nottingham
For direct contact, visit the study record on ClinicalTrials.gov .